Retraction Watch readers may be familiar with the name Piero Anversa. Until several years ago, Anversa, a scientist at Harvard Medical School and the Brigham and Women’s Hospital, was a powerful figure in cardiac stem cell research.
On Wednesday, we reported that a month after media reports of undisclosed conflicts of interest by top brass at Memorial Sloan Kettering Cancer Center, a researcher there had corrected two papers to include financial conflicts of interest.
While we’re still putting finishing touches on it before an official launch, with more than 18,000 retractions, it’s already the most comprehensive collection of retractions anywhere. We have learned a great deal as we’ve gathered those retractions, which we look forward to sharing quite soon, along with ways that the database can help cut down on waste in research, but — and this is key — it has been painstaking work.
Because of how scattered, incomplete, and sometimes even wrong retraction notices are, every retraction must be located, double-checked, and entered by hand. That means all 18,244, at the time of this writing — and growing every day. Our researcher spends much of her time curating the database, assisted at various points by a small army of terrific librarians, graduate students, and others interested in cleaning up the literature.
As you can guess, this effort requires resources. We have been fortunate to have this and other work funded by generous grants over the years, going back to 2014, but those grants have ended. We are always in discussions with past and potential funders — and would be grateful to hear suggestions on that front — but as is the case for most non-profits, our future depends on maintaining sufficient financial support. We’re therefore asking you to consider a tax-deductible financial contribution to our parent non-profit organization, The Center For Scientific Integrity. Continue reading Retraction Watch readers, we need your help to be able to continue our work
A month after a journalism investigation that led to resignations and turmoil at Memorial Sloan Kettering Cancer Center in New York, researchers including a Sloan Kettering scientist have quietly corrected at least two papers to add disclosures of financial conflicts of interest.
A researcher at the University of Kentucky who studies the cancer risks of toxic chemicals has retracted three papers. All of the retraction notices, which appear in the Journal of Biological Chemistry, refer to some kind of image duplication. The papers were originally published between 2014 and 2017, with the 2014 paper cited 39 times, according to Clarivate Analytics’ Web of Science.
The address was supposed to be a triumphant inaugural speech.
On Friday, Leonid Eidelman, the incoming president of the World Medical Association (WMA), made up of representatives from national medical associations, stood up in front of the group’s members in Reykjavik, Iceland, and told them it was a great honor to become their leader.
The trouble was, his speech had lifted passages from various sources — including remarks one of his predecessors had given in 2014. The following morning, members of the Canadian Medical Association (CMA) — including Chris Simpson, who had delivered the original 2014 speech — made a motion for Eidelman to resign. When that failed, the CMA said it was leaving the WMA.
The chief scientific officer of a cannabis product company whose stock price has been hotter than a flaming joint (sorry) was known more than 18 months ago to have committed research misconduct while at the U.S. National Institutes of Health — casting a cloud of suspicion over the firm’s operations.
Marketwatch reported yesterday that the company, India Globalization Capital, which trades on the New York Stock Exchange as IGC, has at least nine other “red flags” for investors, from questions about its ability to manufacture cannabinoids to a history of trouble with the U.S. Securities and Exchange Commission.
Until August, the company’s stock had been trading below 50 cents per share. It began a dramatic rise, eventually reaching $13 per share. MarketWatch notes:
A surgeon in Scotland who mistook a tear duct for a brain tumor, operated on the wrong disc in another patient and eventually gave up his right to practice medicine in the UK has corrected a 2008 paper.
The reason: More confusion, it seems. Muftah Salem Eljamel says he mistook an image in the article as being from his hospital when it belonged to another surgeon at a hospital in Cardiff, some 460 miles distant. And oh, the image wasn’t what he thought it was to begin with. The Courier reported on the correction.